论文部分内容阅读
自1982年Grimm等首先描述了淋巴因子激活的杀伤细胞(Lymphokine activated killer cells,LAK)现象以来,对LAK细胞的研究日益深入。LAK细胞不仅有广谱的体外杀瘤效应,临床应用也具有抗肿瘤作用。LAK细胞和白细胞介素2(Interleukin—2,IL—2)疗法已成为临床上肿廇的继承性免疫治疗的主要方法之一。本文对近年来LAK细胞的研究及在血液病中的临床应用进展做一简要的概述。一、LAK细胞的生物学特性及其制备方法 LAK细胞是淋巴细胞在含有IL—2条件下经短期体外液体培养后能杀伤对自然杀伤(NK)敏感和不敏感的瘤细胞系及原代肿瘤细胞的一类功能细
Since 1982, Grimm et al. First described the phenomenon of Lymphokine activated killer cells (LAK), the research on LAK cells has been deepened. LAK cells not only have broad-spectrum killing effect in vitro, but also have anti-tumor effect in clinical application. LAK cells and Interleukin-2 (IL-2) therapies have become one of the main methods of adoptive immunotherapy for clinically swollen. In this paper, LAK cells in recent years and the clinical application of blood disease in the progress made a brief overview. First, the biological characteristics of LAK cells and their preparation LAK cells are IL-2 containing IL-2 after a short-term liquid culture can kill natural killer (NK) sensitive and insensitive tumor cell lines and primary tumors A class of cell function fine